Eli Lil­ly wraps up fifth and fi­nal tirzepatide PhI­II tri­al, claim­ing a win over Sanofi's Lan­tus. The FDA awaits

Eli Lil­ly has long been test­ing its ex­per­i­men­tal tirzepatide can­di­date in di­a­betes, look­ing to see whether or not it can take over Trulic­i­ty’s di­a­betes man­tle …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER